Regulatory Calendar for Russia and the EAEU, 2026 to 2028

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Over the next 24 months, the key milestones for Russia and the EAEU concentrate on three dates: 1 September 2026, 31 December 2027 and 31 December 2028. A company should use these three dates as anchors and plan its preparation backwards from them: complete the transition of procedures and marking preparation before 1 September 2026; complete new application submissions within 2027; and complete the close-out of variations to existing certificates within 2028. Between the anchors, two secondary dates — 1 September 2027 and 1 January 2028 — carry consequences that are easy to overlook but material.

The calendar approach matters because the milestones are interdependent. The procedural transitions that take effect on 1 September 2026 determine the format of the vigilance and reporting work that runs through 2027 and 2028; the final window for national new applications closes on 31 December 2027 and thereby fixes the queue in the expert organisations through that year; and the close-out of the national rules on 31 December 2028 defines the last date by which variations to existing certificates must have been submitted. Planning the three anchors independently, without the connecting logic, produces schedules that collide in practice.

2. Legal basis

The table below sets out the effective and cut-off dates with the instruments and provisions on which each rests, as summarised from the cited decisions and orders.

Effective / cut-off dateItemLegal basis
2026-09-01Transition of the conformity assessment proceduresПриказ Минздрава России No. 421n (2026-05-13)
2026-09-01Transition of the safety monitoring procedureПриказ Минздрава России No. 540n (2026-05-26)
2026-09-01Transition of the adverse event reporting procedureПриказ Минздрава России No. 541n (2026-05-26)
2026-09-01New rules on imports of unregistered devicesПП РФ No. 557 (2026-05-16)
2026-09-01Mandatory digital marking for newly added categoriesПП РФ No. 375 (2026-04-06)
2027-12-31Final window for submitting new applications under the national rulesProtocol (2025-12-29, Article 11); 288-FZ (2026-08-04)
2027-12-31Expiry of the application of pp. 63, 87, 101ПП РФ No. 2214 (2025-12-30)
2027-09-01Start of the consequence for authorised representative information not updatedПП РФ No. 1684, subparagraph “e” of p. 137
2028-01-01Expiry of the validity of ПП РФ No. 430 and No. 552 (per p. 32 of Order No. 421n)Приказ Минздрава России No. 421n (2026-05-13)
2028-12-31End of the validity of the rules of Decision No. 1684; close-out of variations to existing certificatesПП РФ No. 2214 (2025-12-30)
2032-09-01Expiry of Orders No. 421n, No. 540n, No. 541n and Decision No. 557No. 421n (2026-05-13), No. 540n and No. 541n (2026-05-26), ПП РФ No. 557 (2026-05-16)

3. Expert insights

Insight 1: 1 September 2026 is a dense node at which four instruments take effect simultaneously. Conformity assessment, safety monitoring, adverse event reporting and the import of unregistered devices all transition on the same date, with the expansion of digital marking layered on top. Compliance preparation must therefore run in parallel workstreams rather than sequentially: a company that schedules these transitions one after another will not finish before the effective date, and the failures compound, because the reporting formats, the monitoring procedure and the import rules all change together.

Insight 2: 1 September 2027 is the second node that is easily overlooked. The consequence for authorised representative information not updated starts to run from that date, while the update action itself should have been completed before 1 September 2026 — the two dates are exactly one year apart, and the interval is in substance a remediation window. Companies that read the 2027 date without the 2026 duty will discover that the penalty clock started long after the obligation did.

Insight 3: beyond the three-year horizon there is a long tail. Orders No. 421n, No. 540n and No. 541n and Decision No. 557 all remain applicable until 1 September 2032, which shows that this is a long-term institutional cycle: the investment in getting the procedures, registers and templates right pays back over six years, not over one compliance season.

4. Practical recommendations

Calendar management is a project discipline, and the recommendations below treat the milestones accordingly.

  1. Put the table above into the project management system, and set an internal reminder six months ahead for every row, so that preparation starts before the external deadline approaches.
  2. Re-run the regulatory tracking every six months, focusing on amendments to decisions at the EEC level and on changes in RZN’s enforcement practice.
  3. Use the path decision model of article 20 to review the route selection of each product line once a year, so that national and Union tracks stay aligned with the calendar.
  4. Verify the readiness status of each of the 1 September 2026 items individually, and record the evidence of readiness in the project system rather than in meeting notes.
  5. Assign a single owner for the calendar as a whole, so that amendments found by one function are propagated to every workstream that depends on the affected date.

5. Verification checklist

The checklist below confirms that the calendar is operational, not merely documented.

  • □ The three anchor dates have been entered into the project management system with advance reminders set
  • □ The readiness status of each of the four transition items for 2026-09-01 has been confirmed item by item
  • □ The list of new applications to be submitted before 2027-12-31 has been scheduled
  • □ The plan for closing out variations to existing certificates before 2028-12-31 has been arranged
  • □ A named owner is assigned to the semi-annual regulatory tracking mechanism
  • □ The long tail to 2032-09-01 is recorded in the tracking calendar

Regulatory information verified as of 29 October 2026.

GRZAN helps manufacturers build and maintain their Russian and EAEU regulatory calendars, tracking the milestones of 2026 through 2028 and the long-term instruments running to 2032, alongside post-market compliance services covering vigilance, recalls and federal state supervision readiness. For regulatory calendar and post-market support, contact us at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail